Trial Design & Patient Population
ADRIATIC (NCT03703297) is a randomized, double-blind, placebo-controlled phase III study enrolling 730 patients with Stage I–III limited-stage small-cell lung cancer (LS-SCLC) who had no disease progression after completing concurrent platinum-based chemoradiotherapy (cCRT) .
Patients were randomized into three arms: Durvalumab + placebo
Durvalumab + tremelimumab Dual placebo
This summary focuses on the comparison of durvalumab alone versus placebo .
Primary Findings (First Interim Analysis – ASCO 2024)
Overall Survival (OS): Durvalumab arm: Median OS of 55.9 months Placebo arm: Median OS of 33.4 months Represents nearly a 2-year improvement and a 27% reduction in risk of death (HR = 0.73; P = 0.0104) . Progression-Free Survival (PFS): Durvalumab: 16.6 months Placebo: 9.2 months Resulted in a 24–25% reduction in disease progression risk (HR = 0.76; P = 0.0161) . These improvements were hailed as groundbreaking—the first major advance in limited-stage SCLC in decades—and establish durvalumab consolidation as the new standard of care .
Subgroup & Updated Analyses (ESMO 2024 & Beyond)
Consistency across subgroups: Benefits in OS and PFS were observed regardless of: Receipt of prophylactic cranial irradiation (PCI) Chemotherapy regimen (carboplatin vs cisplatin) Radiation schedule (once vs twice daily) . PCI subgroups: With PCI: 3-year OS of 62.1% (durvalumab) vs 56.5% (placebo) Without PCI: 50.2% vs 37.3%, respectively . Chemotherapy type: The carboplatin subgroup showed unexpectedly superior outcomes with durvalumab versus cisplatin, a finding described as “puzzling” and warranting further investigation . Safety profile: Grade 3–4 treatment-emergent adverse events were comparable across subgroups, though slightly higher with PCI and carboplatin. Treatment discontinuation rates due to side effects were similar between durvalumab and placebo .
Exploratory Findings (2025 Updates)
Metastasis risk reduction: Extrathoracic metastases: Occurred in 18.2% of durvalumab arm vs 25.2% placebo. HR for intrathoracic progression/death: 0.82 HR for extrathoracic progression/death: 0.67 (median not reached) . CNS/brain metastases: 6.8% in durvalumab arm vs 12.4% placebo. HR: 0.64; median not reached . Investigators suggest that durvalumab may reduce brain metastasis risk, potentially through better systemic disease control or treating undetected micrometastases .
Final Takeaway
The ADRIATIC trial represents a major advancement in treating limited-stage small-cell lung cancer, showing that durvalumab consolidation significantly prolongs both survival and disease control after chemoradiotherapy. Its efficacy across diverse patient subgroups and emerging data on metastasis mitigation and immuno-biomarkers highlight its potential to reshape standard treatment and pave the way for more tailored strategies.